ABOUT

Patient-derived tumour xenografts (PDX) are now widely embraced by the scientific community as important preclinical tools for cancer biomarker discovery and drug development. However, they are costly and time-consuming to develop. As such, data sharing and collaboration has been essential to the growth of this research field but is still limited by a lack of central guidance and suitable infrastructures

The EurOPDX Consortium has teamed up with other key academic and SME partners in a four-year project funded by the European Union’s Horizon 2020 research and innovation programme under the topic “Integrating Activities for Starting Communities”. The EDIReX project will build on the experience and successes of the Consortium, offering a cutting-edge, and much needed, EurOPDX Research Infrastructure for PDX research.

EDIReX stands for “EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts” and aims to improve cancer drug development success rates through the enablement of collaborative PDX research. We are indeed developing a user-friendly public repository to facilitate access to the +1500 PDX models from over 30 different cancer types currently curated by the EurOPDX Consortium. To enable effective PDX resource sharing, the project will develop common standards and procedures for PDX biobanking, quality control, and in vivo studies, and offer training in this area. These activities will enable to effective provision of free Trans-national Access (TA) to PDX resources and expertise for academic and industrial cancer researchers from Europe and Worldwide.

Euro PDX Logo